Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029

Design Therapeutics, Inc.

Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.
Cash, equivalents and securities $219.8M as of Dec 31, 2025; runway into 2029.
DT-216P2 (FA) RESTORE-FA trial ongoing; frataxin data expected H2 2026.
DT-168 (FECD) Phase 2 biomarker trial data anticipated H2 2026.
DT-818 (DM1) Phase 1 MAD trial dosing expected H1 2026; results in 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Design Therapeutics, Inc. reported financial results for the three and twelve months ended December 31, 2025.

Period: the three and twelve months ended December 31, 2025
Result: reported results

Exact text from the filing

On March 9, 2026, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-098474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.